Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Completed

Conditions: Gastric Cancer
Esophageal Cancer

Interventions: Drug: carboplatin
Drug: fluorouracil
Drug: paclitaxel
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-03-07

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 56

Registration Number: NCT00022139

Locations: 🇺🇸
Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States
🇺🇸
Southwest Medical Center, Liberal, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States

and more 32 locations

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-05-10

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00055887

Locations: 🇨🇦
CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada
🇺🇸
Schiffler Cancer Center, Wheeling, West Virginia, United States
🇨🇦
Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada

and more 19 locations

Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-09-20

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 400

Registration Number: NCT00055965

Locations: 🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Phase 2

Completed

Conditions: Urethral Cancer
Bladder Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-01-31

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 7

Registration Number: NCT00055835

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States

and more 89 locations

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2013-07-11

Lead Sponsor: Fox Chase Cancer Center

Registration Number: NCT00054392

Locations: 🇺🇸
Fallon Clinic at Worcester Medical Center, Worcester, Massachusetts, United States
🇺🇸
Aultman Hospital Cancer Center at Aultman Health Foundation, Canton, Ohio, United States
🇺🇸
David Lee Outpatient Cancer Center at Charleston Area Medical Center, Charleston, West Virginia, United States

and more 53 locations

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

First Posted Date: 2003-02-06

Last Posted Date: 2020-10-05

Lead Sponsor: CTI BioPharma

Registration Number: NCT00054210

Locations: 🇺🇸
Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
🇺🇸
Omni Healthcare, PA, Melbourne, Florida, United States
🇺🇸
Columbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States

and more 31 locations

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

Phase 2

Completed

Conditions: Myelodysplastic/Myeloproliferative Diseases
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-01-28

Last Posted Date: 2010-06-10

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 42

Registration Number: NCT00053287

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Lymphoma
Neuroblastoma
Retinoblastoma

First Posted Date: 2003-01-28

Last Posted Date: 2011-03-01

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1

Registration Number: NCT00053118

Locations: 🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Lung
Adenosquamous Cell Lung Cancer
Bronchoalveolar Cell Lung Cancer
Large Cell Lung Cancer
Squamous Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: paclitaxel
Drug: gefitinib
Radiation: radiation therapy
Drug: carboplatin
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 144

Registration Number: NCT00040794

Locations: 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2023-06-15

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00006004

Locations: 🇵🇪
Instituto de Enfermedades Neoplasicas, Lima, Peru
🇺🇸
Mercy Medical Center, Des Moines, Iowa, United States
🇺🇸
Iowa Methodist Medical Center, Des Moines, Iowa, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy